On the other hand, Uras et al showed that palbociclib in combination with the mTOR inhibitor everolimus is synergistic and causes a significant decrease in cell viability in FLT3-positive AML cell lines harboring the D835 mutation in comparison to monotherapy.[28] The combination also caused a decrease in ERK signaling. Here, FLT3 is linked to acute myeloid leukemia.